FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to aptamers; it can be used in medicine for use in therapy of a subject for inhibition or suppression of TLR9 activation. The used aptamer consists of a nucleic acid sequence SEQ ID No. 1 (GGT TGG TGT GGT TGG).
EFFECT: invention provides inhibition of TLR9 activation in a subject’s cell by specific interaction of an aptamer with TLR9 receptor.
9 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CPG-OLIGONUCLEOTIDE ANALOGUES, CONTAINING HYDROPHOBIC T-ANALOGUES WITH AMPLIFIED IMMUNOSTIMULATORY ACTIVITY | 2007 |
|
RU2477315C2 |
| IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION | 2003 |
|
RU2338750C2 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| SEMI-SOFT C-CLASS IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2005 |
|
RU2393223C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| COMPLEX CONTAINING AN OLIGONUCLEOTIDE, HAVING IMMUNOSTIMULATING ACTIVITY, AND ITS APPLICATION | 2014 |
|
RU2723943C2 |
| COMPOSITION FOR TREATING CANCER ASSOCIATED WITH HPV INFECTION | 2017 |
|
RU2664466C1 |
| METHOD OF TUMOUR TREATMENT IN SUBJECT | 2006 |
|
RU2404193C2 |
| IMMUNOSTIMULATING OLIGONUCLEOTIDES | 2009 |
|
RU2477753C2 |
